Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Pasteur To Launch Meningococcal Vaccine In China

This article was originally published in PharmAsia News

Executive Summary

Sanofi Pasteur will soon launch its meningococcal polysaccharide vaccine A and C (Menomune A/C) in China, heating up the market after meningococcal vaccine was included in the country's expanded immunity program. According to a China CDC official, as domestic meningococcal vaccine cannot meet the expanded demand, approval of Menomune A/C will provide consumers with more choices. Although local vaccines costing some 20 yuan are administered free for children, the Sanofi Pasteur product will be sold at 128 yuan. Menomune A/C is the only imported meningococcal vaccine approved in China to date and the company targets sales of 2 million doses in the next five years. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068188

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel